Cannabis has been associated with acute cardiovascular complications, including ventricular arrhythmias and myocardial infarction, particularly in otherwise healthy young adults. We report the death of a 28-year-old man who suffered from witnessed ventricular fibrillation while smoking a legally purchased cannabis product labeled as containing 29.9% Δ9-tetrahydrocannabinol (Δ9-THC). Sustained return of spontaneous circulation was achieved after ∼50 minutes of resuscitation. Despite intensive care, severe hypoxic-ischemic encephalopathy developed, and life support was withdrawn 6 days later. Serial ECGs demonstrated evolving ischemic abnormalities accompanied by a dynamic rise in cardiac biomarkers. Autopsy revealed a structurally normal heart with widely patent coronary arteries and patchy acute subendocardial myocardial injury/infarction. Antemortem toxicology demonstrated Δ9-THC and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, confirming cannabis exposure, while comprehensive cardiac genetic testing identified no pathogenic or likely pathogenic variants. The integrated clinical, electrocardiographic, toxicological, pathologic, and genetic findings support acute cannabis-associated cardiovascular toxicity occurring in close temporal association with high-potency cannabis use. Transient myocardial ischemia secondary to coronary vasospasm is favored, although primary ventricular arrhythmia with secondary global ischemia-reperfusion injury cannot be excluded retrospectively. This case highlights the importance of comprehensive clinicopathologic investigation when evaluating sudden cardiovascular collapse following cannabis exposure.
No takes yet. Share an insight, caveat, or question.
Both et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: